Latest News

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.

Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.

Noab Banoub, a third year medical student, describes his journey into medicine and his view of ophthalmology's future.

Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point and beat the dexamethasone implant on visual and anatomic measures at 24 weeks.

At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic exposure.

AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.

Uveitis is uncommon, but it causes a disproportionate share of visual morbidity.

Discover how IRIS Registry real-world data turns EHR notes and images into evidence that speeds ophthalmology trials, recruitment, safety studies, and post-approval insights.

FDA accepts vamikibart BLA for UME as data show sustained gains at 1 year; decision July 2027.

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.

The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.

A successful premium outcome depends not only on the lens, but also on how well the patient understands what to expect before surgery.